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INTRODUCTION 
Diabetes mellitus is a major health problem and causes 
considerable morbidity and mortality, primarily due to micro and macro 
vascular complications. The prevalence of diabetes is increasing globally 
and the maximum increase is expected to be in developing countries like 
India. By the year 2010, it is estimated that nearly 220 million people 
world wide will have diabetes. 
India is predicted to be the capital of diabetes. According to the 
most recent estimates published in the Diabetes Atlas 2006 (2), ‘India has 
the largest number of diabetic patients in the world ,estimated to be about 
40.9 million in the year 2007 and expected to increase to about 69.9 
million by the year 2025’. Diabetes is preventable and so are its 
complications. 
 Type 2 diabetes usually starts in middle age or later. It is the 
common type of diabetes and is thought to be due to both impaired 
insulin secretion and resistance to the action of insulin at its target cells. 
Diabetes affects the small blood vessels (microangiopathy) at least is 
thought to be related to the duration and severity of hyperglycemia1. 
Micro vascular changes would have already started occurring in most of 
the DM type 2 patients at the time of diagnosis itself. This is because 
these patients remain symptom free for long periods before they are 
diagnosed clinically. 
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   The diabetes control and complications trial (DCCT) showed that 
intensive control of the blood sugar over the seven year study interval 
reduced the progression of diabetic neuropathy, retinopathy and 
nephropathy2. The relationship between control and complications in type 
2 diabetes mellitus was evaluated in UKPDS3. The study concluded that 
for every one percent decrease in HbA1c there was 35% reduction in the 
risk of micro vascular complications. 
             Nephropathy is a major cause of illness and death in diabetes. 
Indeed the excess mortality in diabetes occurs mainly in proteinuric 
diabetic patients and results not only from end-stage renal disease but 
also from cardiovascular disease (CVD), particularly in type 2 diabetic 
patients4. The risk for cardiovascular disease was 3 fold higher in South 
Indian Diabetic nephropathic patients when compared with their non-
nephropathic counter parts5. A reduction of micro albuminuria in Type 2 
diabetic patients is an integrated indicator for renal and cardiovascular 
risk reduction6. 
  Although proteinuria had been demonstrated in diabetic patients 
since 18th century, it was Bright who in 1836 postulated that albuminuria 
could reflect a serious renal disease specific to diabetes4. One hundred 
years later Kimmelstiel and Wilson7 described the nodular glomerular 
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intercapillary lesions in long-standing type 2 diabetes patients suffering 
from the clinical syndrome of heavy proteinuria and renal failure 
accompanied by arterial hypertension. The relationship between arterial 
blood pressure and diabetic nephropathy seems to be complex one, 
nephropathy increasing blood pressure and blood pressure accelerating 
the course of the nephropathy8. 
  It is estimated that 20% of type 2 diabetes patients reach ESRD 
during their lifetime9. Detecting the patients in the early stage of 
nephropathy and thereby timely intervention prevents as well as retards 
the progression towards ESRD and also these patients should be screened 
for coronary heart disease and to be managed appropriately. 
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AIM 
The aims of the study are: 
1. To determine the prevalence of Diabetic Nephropathy in Newly 
Detected type 2 diabetic patients. 
2. To analyze the risk factors associated with the development of 
Diabetic Nephropathy. 
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REVIEW OF LITERATURE 
  Diabetes mellitus is the leading cause of chronic kidney disease 
(CKD) all over the world. It is the most disabling complication of 
diabetes which accounts for 20-40% of all causes of CKD. It is estimated 
that over 43% of the patients developing ESRD have diabetes as the 
cause10. 
 Persistent albuminuria is the hallmark of diabetic nephropathy 
which can be diagnosed clinically if the following additional criteria are 
fulfilled: presence of diabetic retinopathy and the absence of clinical or 
laboratory evidence of other kidney or renal tract disease4. 
 During the last decade several longitudinal studies have showed 
that raised urinary albumin excretion below the level of clinical 
albuminuria, so called microalbuminuria, strongly predicts the 
development of diabetic nephropathy. 
According to the Mogensen’s staging system, Diabetic 
nephropathy consists of five stages which include microalbuminuria as 
stage 3, also known as incipient nephropathy. 
 Microalbuminuria was first defined in 1982 by the Guys Hospital 
Group and referred as subclinical increase in urine albumin excretion in 
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insulin dependent diabetics which strongly predicted the subsequent 
development of overt diabetic nephropathy. Microalbuminuria was soon 
after reported to predict clinical proteinuria and also early mortality in 
type 2 diabetes. 
Pathogenesis11 
  The pathogenesis of diabetic glomeruloscerosis is intimately 
linked with that of generalized diabetic microangiopathy. 
- The bulk of the evidence suggests that diabetic 
glomerulosclerosis is caused by the metabolic defect, that is, 
the insulin deficiency, the resultant hyperglycemia, or some 
other aspects of glucose intolerance. These metabolic defects 
are responsible for biochemical alterations in GBM, including 
increased amount and synthesis of collagen type IV and 
fibronectin and decreased synthesis of the heparan sulfate 
proteoglycan. 
- Nonenzymatic glycosylation of proteins is known to occur in 
diabetics and gives rise to advanced glycosylation end (AGE) 
products, may contribute to the glomerulopathy. 
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One hypothesis implicates hemodynamic changes in the initiation 
and progression of diabetic glomerulosclerosis. It is well known that the 
early stages of diabetic nephropathy are characterized by an increased 
GFR with increased glomerular capillary pressure and glomerular 
hypertrophy with increased glomerular filtration area.  
Pathology11 
The following morphological patterns are seen in diabetic 
nephropathy: 
Glomerular Basement Membrane Thickening  
Widespread thickening of the glomerular capillary basement 
membrane (GBM) occur virtually in all diabetics, irrespective of the 
presence of proteinuria. This thickening begins as early as 2 years after 
the onset of type 1 diabetes and by 5 years amounts to about a 30% 
increase. The thickening continues progressively and usually concurrently 
with mesangial expansion. Simultaneously there is thickening of the 
tubular basement membranes. 
Diffuse Mesangial Expansion  
This lesion consists of diffuse increase in mesangial matrix. As the 
disease progresses, the expansion of mesangial areas can extend to 
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Fig. 1. Nodular Glomeruloscerosis 
nodular configurations. The progressive expansion of the mesangium has 
been shown to correlate well with measures of deteriorating renal 
function such as increasing proteinuria. 
Nodular Glomeruloscerosis 
This is known as intercapillary glomerlosclerosis or Kimmelstiel 
Wilson disease. The glomerular lesions take the form of ovoid or 
spherical, often laminated, nodules of matrix situated in the periphery of 
the glomerulus. The nodules are PAS positive. As the disease advances, 
the individual nodules enlarge and may eventually compress and engulf 
capillaries, obliterating the glomerular tuft. As a consequence of 
glomerular and arteriolar lesion, the kidney suffers from ischemia, 
develops tubular atrophy and interstitial fibrosis and usually undergoes 
overall contraction in size. 
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Pathology of Diabetic Nephropathy in Patients with Diabetes and 
Proteinuria (Table - 1)4 
 
Always Present Often or Usually Present Sometimes Present 
Glomerular basement membrane 
thickening[*] 
Kimmelstiel-Wilson nodules 
(nodular glomerulosclerosis)[*]; 
global glomerular sclerosis; focal-
segmental glomerulosclerosis, 
atubular glomeruli 
Hyaline “exudative” 
lesions (subendothelial)[†] 
Tubular basement membrane 
thickening[*] 
Foci of tubular atrophy Capsular drops[†] 
Mesangial expansion with 
predominance of increased 
mesangial matrix (diffuse 
glomerulosclerosis)[*] 
  Atherosclerosis 
Interstitial expansion with 
predominance of increased 
extracellular matrix material 
  Glomerular 
microaneurysms 
Increased glomerular basement 
membrane, tubular basement 
membrane, and Bowman capsule 
staining for albumin and IgG[*] 
Afferent and efferent arteriolar 
hyalinosis[*] 
  
 
 [*] In combination, diagnostic of diabetic nephropathy. 
[†] Highly characteristic of diabetic nephropathy 
Nodular glomeruloscerosis and diffuse mesangial sclerosis are 
fundamentally similar lesions of the mesangium. The nodular lesion, 
however, is highly but not completely specific for diabetes, as long as 
care is taken to exclude MPGN, the glomerulopathy associated with light 
chain and monoclonal immunoglobulin deposition disease, amyloidosis 
and a few rare entities which can have a similar appearance. 
Approximately 15-30% of patients with long term diabetes develop 
Nodular glomeruloscerosis, and in most instances it is associated with 
renal failure. 
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Screening for diabetic nephropathy 
Primary prevention of diabetic nephropathy is possible with 
vigorous glucose and blood pressure control. Screening for diabetic renal 
disease falls within the scope of secondary prevention. 
Recommendation for screening 
The American Diabetic Association in concert with National 
Kidney Foundation recommended screening for microalbuminuria 
starting at diagnosis of type 2 diabetes and patients with type 1 diabetes 
longer than 5 years12. Since microalbuminuria can present during an 
episode of urinary tract infection, exercise, stress and fluctuation of urine 
albumin excretion is well known, it is recommended to have at least 2 or 
3 samples tested in the course of six months. 
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Fig. 2 
A suggested path for screening for diabetic nephropathy 
(The American Diabetic Association) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Choice of screening test 
At present two general classes of tests are used to screen for 
diabetic nephropathy:   1. GFR     2. Albuminuria.  
Tests for microalbuminuria 
Positive for albumin 
Conditions that may invalidate 
urine albumin excretion
Treat and/or wait until resolved. 
Repeat test for positive protein
Repeat microalbuminuria test 
Twice within 2-3 months
 
2 of 3 tests positive? 
Microalbuminuria,  
begin treatment 
Yes 
No Yes 
Yes 
 
Re screen in one 
year 
No 
No 
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GFR: It can be estimated conveniently with a creatinine value 
incorporating in to prediction equations such as MDRD13 (Modification 
of Diet in Renal Disease) or CG (Cockrauft-Gault). In diabetic 
nephropathy the GFR can be normal even in stage of overt nephropathy. 
In addition when GFR is descended into clearly abnormal range, much of 
the course of diabetic nephropathy has been run and opportunity for 
intervention become minimal. Thus GFR decline is a late index of kidney 
damage especially in diabetic renal disease and it is not a very good early 
marker for screening. 
MDRD Equation: 
GFR (mL/min/1.73m2) = 186.3 x Pcr (e-1.154) x age(e-0.203) x (0.742 
if female) x (1.21 if black) 
Albuminuria: Urinary albumin excretion rate (UAER) remains the 
cornerstone of early detection of diabetic nephropathy and it is the 
recommended screening test for diagnosis of diabetic nephropathy14.  
Atleast 2 or 3 samples  within six months period should be positive 
before designating a patient has microalbuminuria. 
Diagnosis of diabetic nephropathy 
The diagnosis of diabetic nephropathy can be made by 1) Urinary 
albumin excretion rate  2) GFR estimation 3) Serum creatinine 4) Renal 
biopsy 
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Urinary albumin excretion rate (UAER) 
  The total urinary protein excretion is not a good indicator of the 
macromolecular permeability defect in the early stages of diabetic kidney 
disease. Direct measurement of urine albumin excretion increases the 
accuracy. Persistent microalbuminuria is the earliest reliable predictor 
and marker of diabetic nephropathy. Microalbuminuria is defined as 24 
hours urinary albumin excretion rate (UAER) between 30-300 mg/day or 
20-200 µg/min, equivalent to 0.46-4.6 µmol/24 hours. If a timed 
collection of urine cannot be obtained a random sample index of 
albumin/creatinine (µg/mmol) can be calculated, and microalbuminuria is 
present at an index >3.5 (sensitivity>95%, specificity>65%).  
The detection of microalbuminuria denotes stage 3 nephropathy or 
incipient nephropathy. 
Several methods are available to measure microalbuminuria such 
as radioimmunoassay, nephelometric immunoassay, Enzyme Linked 
Immuno Sorbent Assay (ELISA) and semi quantitative dipstick test 
(Micral test). 
 Once the urine albumin excretion rate (UAER) exceeds >300mg in 
24 hrs or >200µg/min equivalent to 500 mg protein excretion per day, it 
is defined as macroalbuminuria or clinical or overt nephropathy. The 
detection of macroalbuminuria denotes stage 4 or  Overt nephropathy. 
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Dipstick Detection of Microalbuminuria15 
Micral-Test is an immunochemically based urinary dipstick for the 
semi quantitative determination of microalbuminuria. According to a 
study of 298 consecutive 24 hour collections performed in diabetic 
subjects16, when compared with Radioimmunoassay a Micral test result 
of more than 20mg/L  had a sensitivity of 92.2% , specificity of 92.3% in 
predicting an AER > 20microgram/min. 
GFR estimation 
  The GFR can be high or high normal in the early stages of 
nephropathy (stage 1-3) and normal or low normal in the later stage 
(stage 4-5). GFR estimation in a diabetic patient is more useful to initiate 
intervention in the early stages especially in type 1 diabetes. The 4 
variable MDRD equation is simple and used in most laboratories provide 
GFR based on a single creatinine value. 
Serum creatinine 
  Serum creatinine is a simple test but relatively late marker of 
diabetic renal disease and usually not elevated until diabetic nephropathy 
is advanced (stage 4). Variations in calibration and improper 
standardization of the machines give high or low values which is a major 
limitation. An elevated creatinine in a diabetic nephropathy is the cause 
of renal failure when it is associated with significant proteinuria. 
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Renal biopsy 
  Renal biopsy is not usually done to diagnose diabetic nephropathy. 
Abnormal renal histology in diabetic nephropathy is seen from stage 2 
disease where early basement thickening is seen. In subsequent stages 
(stage 3 and 4) there is progressive increase in the mesangial matrix and 
increased thickness of basement membrane. The classical lesion diffuse 
glomerulosclerosis is seen in stage 4 and 5 nephropathy and nodular 
sclerotic lesions (kimmelstiel-wilson). Though not pathognomonic, is an 
important pathological lesion in diabetic nephropathy. Additional 
findings such as fibrin cap, capsular drops along with hyaline lesions in 
afferent and efferent arteries may be seen in diabetic nephropathy. 
Immunoflorescence studies reveal no immune deposits or scanty linear 
IgG deposits in the capillary loops. Presence of these findings would 
support diagnosis of diabetic nephropathy in a diabetic patient who has 1) 
minimal proteinuria 2) active urine sediment with RBC casts in urine 3) 
the duration of diabetes is short 4) absence of diabetic retinopathy 
 On the basis of current knowledge, the following recommendations 
have been made for the use of renal biopsy on clinical grounds alone15. 
Biopsy on clinical grounds alone if, 
a) IDDM<10 year and absence of any diabetic retinopathy with 
clinical evidence of renal disease, 
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b) NIDDM with clinical renal disease in absence of background or 
proliferative retionopathy independent of duration 
c) If rate of decline of GFR or rise in AER falls outside established 
norms or when clinical and laboratory findings indicate 
increased likelihood of non-diabetic renal disease. 
d) IDDM in whom a multisystem disease (eg.Systemic Lupus 
Erythematosis) is suspected or present. 
Markers other than microalbuminuria 
  Microalbuminuria is relatively a late marker to diagnose 
nephropathy, because there have been studies demonstrated advanced 
renal lesions on renal biopsies by the time microalbuminuria is present. 
There is intensive research to identify earlier clinical/biochemical 
(phenotypic) or DNA defect (genotypic) that would predict with high 
sensitivity and specificity the susceptibility to diabetic nephropathy 
before actual development of the disease. Of these genes coding for renin 
angiotensin system and especially genes coding for ACE, have attracted 
most interest. Three genotypes of insertion /deletion ACE gene 
polymorphism (II, ID, DD) has been found in the population17. Studies on 
human kidneys revealed highest tissue ACE and mRNA levels in 
glomeruli and tubule of subjects with DD genotype compared with other 
genotypes. Marre et al.18 demonstrated alterations in glomerular 
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hemodynamics with DD or ID ACE genotypes when acute 
hyperglycemia induced normotensive and normoalbuminuric type 1 
diabetic patients. Based on the evidence patients with ID or DD genotype 
likely to develop severe renal disease, may be resistant ACE inhibitors or 
Angiotensin receptor blockers(ARB) therapy and thus progress rapidly to 
ESRD19. 
Natural course of Diabetic Nephropathy  
The characteristic clinical stages of diabetic nephropathy are best 
understood in the setting of type 1  diabetes. Most of these young patients 
do not have any coexisting illness and time of onset of diabetes is abrupt, 
therefore the ensuing renal injury after a mean period of 10 years or 
longer can regularly attributed exclusively to diabetes. Type 2 diabetes 
patients may have other coexisting disease including hypertension, and 
renal disease in this  patients can be attributed to diabetes only in 75% 
cases. Furthermore type 2 diabetes is usually diagnosed after actual onset 
of the disease ,  which is often indolent, so the characteristic of the early 
clinical stages of kidney involvement often difficult to delineate . 
However in pima Indians it has been shown that progression of the 
disease advances through the similar stages in as it does in type 1 
diabetes. Diabetic nephropathy can be conveniently characterized into 
different stages as mentioned in the following (Table - 2)20.  
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Table - 2 
 
Stage GFR Albuminuria Blood 
Pressure 
Time Course 
Stage 1  
RenalHypertrophy 
 
Elevated 
(20%-50%) 
Absent Normal At diagnosis 
Stage 2 
Normoalbuminuria 
Elevated 12 – 20 
µg/min 
Normal 5 years 
Stage 3 
Microalbuminuria 
Elevated 20 – 200 
µg/min 
Normal or 
increased 
6 – 15 years 
Stage 4 
Clinical or overt 
Nephropathy 
 
Decreased > 200 µg/min Elevated 20 – 25 years 
Stage 5 
ESRD 
<10 ml/min > 200 µg/min Elevated 25 – 30 years 
 
Stage 1: 
This early stage manifests renal hypertrophy, elevated renal biood 
flow, and increased GFR (20-40%). Urine albumin excretion and blood 
pressure is typically normal. In type 2 diabetes the elevation GFR is 
modest(15-20%). Aggressive pharmacological interventions to achieve 
good glycemic control at this stage reverse the changes. 
Stage 2: 
 This stage is almost similar to stage 1 where almost all patients 
have normoalbuminuria (urinary AER less than 20 mic.gm/ min). The 
GFR is still elevated and blood pressure usually within the normal range 
or it may increase. The renal histology reveals basement membrane 
thickening. Pharmological interventions at this stage may reverse both the 
elevated GFR and the histological changes. 
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Stage 3: 
 This is the stage of microalbuminuria characterized by urine AER 
20- 200 µg/min. It typically occurs 6 - 15 years after the onset of type 1 
diabetes. The GFR is still elevated and the blood pressure usually starts 
rising (increase by 3mm Hg/year if untreated). The renal histology 
reveals basement membrane thickening and mesangial matrix expansion. 
Aggressive pharmacological interventions at this stage reduce 
microalbuminuria and may prevent developing overt nephropathy. The 
histological changes may partially reverse. 
Stage 4: 
 This stage is called as stage of overt or clinical nephropathy which 
is usually seen after 15-25 years the onset of diabetes. It is characterized 
by urinary AER more than 200µg/min or proteinuria more than 
500mg/day. The GFR starts declining at the rate of 10ml/min/year and 
blood pressure is often elevated (increase by 5mmHg/year if untreated). 
The renal histology reveals diffuse mesangial expansion and may have 
closure of glomerular capillaries. The disease is typically progressive 
even with interventions. Aggressive blood pressure control and 
modification dietary protein are the main stay of therapy. Once overt 
nephropathy develops there is a progressive decline in GFR that can be 
assessed as an absolute decline in ml/min/per year. In the absence of 
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glycemic control and blood pressure control albumin excretion increases 
at 20 to 40% per year and GFR decline at a rate of 10 ml/min/year. 
Stage 5: 
 This stage is final outcome after 25-30 years after onset of the 
disease. The GFR is less than 10 ml/min and associated with marked 
proteinuria and the severity of hypertension has major impact on 
progression. The renal histology shows glomerular closure and advanced 
nephropathy. 
Common Progression promoters of diabetic nephropathy 
The promoters of progression are almost similar in both diabetic 
and non diabetic renal disease. However severity of proteinuria rather 
than the underlying disease per se predicts the outcome. The metabolic 
sequelae of chronic hyperglycemia comprise the central biochemical 
abnormalities of diabetes. Genetic and haemodynamic factors must be 
operative in patients at risk for development of diabetic nephropathy, 
because nephropathy does not develop in all diabetic patients. The factors 
predicting a high risk in addition to poor glycemic control include 
duration of diabetes (more than ten years), haemodynamic injury 
(systemic and intraglomerular hypertension), familial/genetic factors, and 
racial predisposition. 
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  Patients with early diabetes –especially type 1, and lesser extent 
type 2 tend to have higher GFR. This occurs due to the increased 
vasodilators (prostanoids, nitric oxide) and increased sodium-glucose 
reabsorption in proximal tubule, which leads to reduced delivery of 
sodium to distal part of nephron, resulting in afferent arteriolar dilatation 
due to altered tubuloglomerular feedback. The increased vasodilatation of 
afferent arteriole increase the single nephron GFR (SNGFR) as a result of 
increased glomerular blood flow (QA) and glomerular capillary pressure 
(PGc). A host of metabolic consequences related to hyperglycemia 
(increased activity of polyol pathway, increased glucosamine metabolism 
and protein kinase C activity (PKC), non enzymatic glycation of proteins) 
contribute to development of nephropathy. Hyperlipidemia may lead to 
increased formation of oxidized LDL in the mesangial cells which result 
in activation of inflammatory response, subsequently fibrosis and 
sclerosis. 
   Genetic factors considered to play a role in progression. First one 
third of patients invariably develop diabetic nephropathy, even when 
blood glucose control is excellent. Second, the incidence of diabetic 
nephropathy decreases after 25-30 years in type 1 diabetes again 
suggesting genetic factor in the development of nephropathy.In addition 
there is strong evidence for familial clustering of diabetic nephropathy. 
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Siblings of type 1 diabetic patients with nephropathy have 2.5-5 times 
higher risk of developing diabetic kidney disease and similar findings in 
Pima Indians and African-Americans with type 2 diabetes. Pima Indians 
are at three fold increased risk for diabetic kidney disease if another 
family member has diabetic nephropathy21. 
Primary and Secondary  prevention of diabetic nephropathy 
It is well established that angiotensin converting enzyme (ACE) 
inhibitors delay the progression of Incipient Nephropathy to overt 
Diabetic Nephropathy (secondary prevention) either in type 1 or in type 2 
Diabetes and remarkably decrease disease progression to uremia and 
overall cardiovascular mortality in patients with overt Diabetic 
Nephropathy. Whether early treatment with ACE inhibitors in 
normoalbuminuric diabetic patients may effectively prevent progression 
to microalbuminuria (primary prevention) is not established so far. 
However, preliminary evidence is available that the incidence of 
microalbuminuria may be reduced by ACE inhibition therapy in 
hypertensive type 2 Diabetes patients. 
Calcium channel blockers (CCBs) inhibit the vasoconstrictor as 
well as both the hypertrophic and hyperplastic effects of angiotensin II 
and other mitogens on mesangial and vascular smooth muscle cells 
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through blockade of calcium dependent mechanisms. Early studies, 
however, demonstrate marked differences between the antiproteinuric 
effects of dihydropyridine. CCBs and nondihydropyridine CCBs 
(verapamil and diltiazem). 
Recent data support the concept that differences in antiproteinuric 
response subclasses relate to their differential effects on glomerular 
permeability, that is, dihydropyridine CCBs do not ameliorate glomerular 
barrier perm-selectivity whereas nondihydropyridine CCBs attenuate it. 
Failure to restore the sieving properties of the glomerular barrier 
increases protein ultrafiltration and enhanced protein traffic in the long-
term contributes to the progression of renal injury independently of the 
underlying renal disease.22 
Recent studies found that nondihydropyridine CCBs may have the 
same reno-protective potential of ACE inhibitors either in experimental 
models of Progressive renal disease and in type 2 Diabetes patients. The 
association of ACE inhibitors with nondihydropyridine CCBs may even 
more effectively than the two agents alone decrease, at comparable level 
of blood pressure control, proteinuria and prevent glomerulosclerosis in 
experimental diabetes and in hypertensive stroke-prone rats.22 
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Additionally, recent studies document that the association of ACE 
inhibitors with nondihydropyridine CCBs reduces urinary albumin 
excretion rate more effectively than the two agents alone in hypertensive 
type 2 Diabetes patients either with incipient or overt nephropathy. 
Furthermore, in proteinuric type 2 Diabetes patients, the combination of 
these classes of agents appears to slow GFR decline and to yield the 
lowest side effect profile over either agent alone in diabetic patients with 
overt nephropathy.22 
Lastly, the association of a calcium channel blocker to ACE 
inhibition therapy in hypertensive diabetics may reduce the need for 
additional diuretic therapy that has been associated with an excess 
mortality in diabetes mellitus. However, whether the association may 
more effectively than ACE inhibitors alone prevent the onset of 
microalbuminuria (primary prevention) or delay the progression from 
microalbuminuria to macroalbuminuria (secondary prevention) is not 
established so far. 
UKPDS-743 states that development of Albuminuria or renal 
impairment was independently associated with increased base line 
systolic blood pressure , urinary albumin, plasma creatinine, and Indian-
Asian ethnicity. Additional independent risk factors for Albuminuria 
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were male sex, increased waist circumference, plasma triglycerides, LDL 
cholesterol, HbA1C, increased white cell count, ever having smoked and 
previous retinopathy. Intensive measures are to be taken to control above 
mentioned risk factors so that the development of Diabetic Nephropathy 
can be prevented . 
Risk Factors/Markers for Development of Diabetic 
Nephropathy in Type 1 and Type 2 Diabetic Patients (Table - 3)4 
Risk Factors/Markers Type 1 Type 2 
Normoalbuminuria (above median) + + 
Microalbuminuria + + 
Sex M > F M > F 
Familial clustering + + 
Predisposition to arterial hypertension +/- + 
Increased sodium/lithium counter transport +/- - 
Ethnic conditions + + 
Onset of IDDM before 20 years of age + ? 
Glycemic control  + + 
Hyperfiltration +/- +/- 
Prorenin + ? 
Smoking + + 
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Treatment of  Diabetic Nephropathy23 
The optimal therapy for diabetic nephropathy is prevention  
by control of glycemia. As part of comprehensive diabetes care, 
microalbuminuria should be detected at an early stage when effective 
therapies can be instituted. Annual measurement of the serum creatinine 
to estimate GFR is recommended. Interventions effective in slowing 
progression from microalbuminuria to macroalbuminuria include: (1) 
normalization of glycaemia, (2) strict blood pressure control, and (3) 
administration of ACE inhibitors or ARBs. Dyslipidemia should also be 
treated. 
Improved glycemic control reduces the rate at which 
microalbuminuria appears and progresses in type 1 and type 2 DM. 
However, once macroalbuminuria exists, it is unclear whether improved 
glycemic control will slow progression of renal disease. During the phase 
of declining renal function, insulin requirements may fall as the kidney is 
a site of insulin degradation. Furthermore, many glucose-lowering 
medications (sulfonylureas and metformin) are contraindicated in 
advanced renal insufficiency. 
 27
Many individuals with type 1 or type 2 DM develop hypertension. 
Numerous studies in both type 1 and type 2 DM demonstrate the 
effectiveness of strict blood pressure control in reducing albumin 
excretion and slowing the decline in renal function. Blood pressure 
should be maintained at <130/80 mmHg in diabetic individuals without 
proteinuria. A slightly lower blood pressure (125/75) should be 
considered for individuals with microalbuminuria or macroalbuminuria. 
Either ACE inhibitors or ARBs should be used to reduce the 
progression from microalbuminuria to macroalbuminuria and the 
associated decline in GFR that accompanies macroalbuminuria in 
individuals with type 1 or type 2 DM. Although direct comparisons of 
ACE inhibitors and ARBs are lacking, most experts believe that the two 
classes of drugs are equivalent in the patient with diabetes. ARBs can be 
used as an alternative in patients who develop ACE inhibitor–associated 
cough or angioedema. After 2–3 months of therapy in patients with 
microalbuminuria, the drug dose is increased until either the 
microalbuminuria disappears or the maximum dose is reached. If use of 
either ACE inhibitors or ARBs is not possible, then calcium channel 
blockers (non-dihydropyridine class), beta blockers, or diuretics should 
be used. However, their efficacy in slowing the fall in the GFR is not 
proven. Blood pressure control with any agent is extremely important, but 
a drug-specific benefit in diabetic nephropathy, independent of blood 
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pressure control, has been shown only for ACE inhibitors and ARBs in 
patients with DM. 
The ADA suggests modest restriction of protein intake in  
diabetic individuals with microalbuminuria (0.8 g/kg per day) or 
macroalbuminuria (<0.8 g/kg per day, which is the adult Recommended 
Daily Allowance, or ~10% of the daily caloric intake). 
Once macroalbuminuria ensues, the likelihood of ESRD is very 
high. As compared to nondiabetic individuals, hemodialysis in patients 
with DM is associated with more frequent complications, such as 
hypotension (due to autonomic neuropathy or loss of reflex tachycardia), 
more difficult vascular access, and accelerated progression of retinopathy. 
Survival after the onset of ESRD is shorter in the diabetic population 
compared to nondiabetics with similar clinical features. Atherosclerosis is 
the leading cause of death in diabetic individuals on dialysis, and 
hyperlipidemia should be treated aggressively. Renal transplantation from 
a living-related donor is the preferred therapy but requires chronic 
immunosuppression. Combined pancreas-kidney transplant offers the 
promise of normoglycemia and freedom from dialysis. 
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MATERIALS AND METHODS 
1. Study group: Newly detected type 2 Diabetes subjects (n=200) 
from Diabetes clinic, Department of Diabetology, Kilpauk Medical 
college, Chennai. The study was conducted over a 8 month period 
from Jan 2008 to Aug 2008. 
2. Study design: Cross sectional study. 
3. Materials: Questionnaire, BMI calculation, Blood pressure, Lipid 
profile, Blood Urea,  Serum creatinine, , GFR calculation,  
Urinalysis, urine PCR (Protein Creatinine Ratio), Micralbuminuria 
(MICRAL strip test), Fundus examination, Ultrasound KUB. 
BMI calculation 
Body mass index (BMI) is calculated with height and weight of the 
subject using the following   formula. 
BMI= weight (kg) / height (m)2  
Blood pressure 
Right upper arm blood pressure is taken in supine position by using 
sphygmomanometer under appropriate condition. 
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Lipid Profile 
Triglyceride (TGL), Low Density Lipoprotein (LDL) and High 
Density Lipoprotein (HDL) levels were estimated and calculated using 
standard methods in the early morning fasting Blood Sample. 
Renal function test 
 Blood samples are collected for blood urea and serum creatinine 
and analyzed in the laboratory at KMCH, Chennai. The Blood Urea in 
this study was estimated using DAM method (Diacetyl Monoxime). 
Serum creatinine was estimated using Modified Jaffe’s method. 
GFR calculation 
GFR is calculated using MDRD formula. 
GFR (mL/min/1.73m2) = 186.3 x Pcr (e-1.154) x age(e-0.203) x (0.742 
if female) x (1.21 if black). 
The following website was used for doing the calculation: 
www.kidney.org/professionals/kdoqi/gfr_calculator.cfm. 
Urinalysis 
Urine sample is collected for urine routine analysis which includes 
sugar, protein, cytology and urinary sediments, and also for culture and 
sensitivity. 
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Urine spot PCR 
Urine sample is collected to estimate protein creatinine ratio. Sulfo 
salicylic precipitation method used for protein estimation. 
Urine Dipstick test 
MICRAL test strips used to detect the presence of 
microalbuminuria in the early morning sample. 
Fundus examination 
 Fundus examination is done for all the subjects with direct 
ophthalmoscope. 
USG  KUB 
Ultrasound KUB was done to find out renal size and to rule out 
non-diabetic causes of nephropathy. 
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Inclusion criteria  
Newly detected type 2 diabetes mellitus subjects. 
Exclusion criteria 
• Patients not willing for study 
• Patients with uncontrolled hypertension 
• Patients with poor glycemic control. 
• Patients with urinary tract infection. 
• Patients with cardiac failure. 
• Patients suspected to have non-Diabetic Nephropathy like 
USGKUB showing contracted kidney, cystic renal disease etc. 
• Patients with other medical illness 
DEFINITIONS 
Diabetes Mellitus 
The WHO in consultation with an expert committee of the 
American Diabetes Association has approved the following diagnostic 
criteria for Diabetes Mellitus. OGTT was done with 75gm glucose in 
250ml of water as per WHO recommendation. 
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Table – 4 
 
CATEGORY FPG PPG 
Normal <100 mg/ dL 
(5.6 mmol/L) 
<140 mg/dL 
(7.8 mmol/L) 
IFG 100-125 mg/ dL 
(5.6-6.9 mmol/L) 
- 
IGT - 140-199 mg/ dL 
(7.8-11.0 mmol/L) 
Diabetes ≥ 126 mg/dL 
(7.0 mmol/L) 
≥ 200 mg/dL 
(11.1 mmol/L) 
Fasting: No caloric intake for atleast 8 hours. 
2-3 days of unrestricted carbohydrated diet prior to the test. 
No physical activities during the procedures. 
Newly detected type 2 Diabetes 
Type 2 diabetic patients of less than 6 months duration from the 
diagnosis are taken as the study subjects. 
Microalbuminuria 
It is defined as urinary albumin excretion greater than 30 mg/24 
hours (20 µg/min), and less than or equal to 300 mg/24hours (200µg/min) 
irrespective of how the urine is collected. Atleast two out of three 
samples collected within 6 months period under optimal conditions 
should be positive to call it as persistent microalbuminuria (stage 3 
diabetic Nephropathy)2. 
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In this study Micral dip stick showing positivity more than  
20 mg/L has taken as Microalbuminuria. Protein creatinine ratio also 
considered and correlated with this result. PCR Value of >0.03 to 0.3 is 
considered as excretion of about 30 mg to 300 mg in 24 hours. Both  
showed one/ one correlation in our study. 
Macroalbuminuria 
It is defined as persistent albuminuria greater than 300 mg/24 hours 
or 200 µg/min (AER).2 
Diabetic Retinopathy 
The minimum criterion for diagnosis of diabetic retinopathy is the 
presence of atleast one definite microaneurysm in any of the visualized 
fields. 
Systemic Hypertension (As per the JNC VII Guidelines) 
Subjects with self reported hypertension and those who had a 
systolic blood pressure of ≥ 140 mmHg and / or diastolic blood pressure  
≥ 90 mmHg were considered to have hypertension. JNC VII recommends 
cut off value of ≤ 130/80 mmHg for good control of systemic 
hypertension in diabetic subjects. 
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Controlled Hypertension 
 Subjects with systemic hypertension having blood pressure 
≤130/80 mmHg with therapeutic intervention.. ACE Inhibitors and 
nondihydropyridine CCBs were not used for the control of blood pressure 
since they have modifying effect on proteinuria.  
In this study only Normotensive and controlled hypertensive 
patients are taken as study subjects. Those who had uncontrolled 
hypertension are not included in this study so that false positivity due to 
uncontrolled hypertension while the detection of Albuminuria is 
eliminated. 
Dyslipidemia 
 Adult Treatment Panel III (ATP III) guidelines developed by the 
National Cholesterol Education Program have been used to detect 
dyslipidemia in the study subjects. According to the guidelines:  
Table - 5 
TYPE 
Cut off values (mg/ dl) 
TGL Dyslipidemia ≥ 150 
LDL Dyslipidemia > 100 
HDL Dyslipidemia < 40 
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Overweight and Obesity 
 The following classification adopted from National Institute of 
Health, National Heart, Lung and blood Institute recognized by WHO is 
used for classifying the subjects according to the weight status. 
Table - 6 
BMI GROUP BMI(kg/m2) 
Underweight < 18.5 
Healthy weight (normal) 18.5-24.9 
Overweight 25.0-29.9 
Obesity ≥ 30.0 
 
Stastistical Analysis 
 The statistical methods used for analysis were 
1) Chi-square test 
2) Two sample ‘t’ test 
3) Binary logistic regression model 
All Analysis was done using Windows- based SPSS statistical 
package (version 11.5). 
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RESULTS 
Total No. of subjects in the study – 200. 
No. of  Males – 70 (35%). 
No. of  Females – 130 (65%). 
Age distribution in the study population 
Table - 7 
Age group (Yrs) No. of subject Percentage 
31-40 40 20.0 
41-50 78 39.0 
51-60 66 33.0 
above 60 16 8.0 
Total 200 100 
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Chart 1: Age distribution in the study population
 
 38
Age distribution in the Diabetic Nephropathy Group 
Table - 8 
Age group (Yrs) No. of subject Percentage 
31-40 4 15.4% 
41-50 10 38.5% 
51-60 10 38.5% 
above 60 2 7.7% 
Total 26 100% 
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 Chart 2: Age distribution in Diabetic Nephropathy 
Group
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Distribution of Subjects according to B.M.I. 
Table - 9 
BMI Group (Kg/m2) No. of subject Percentage 
< 18.5 2 1.0 
18.5-24.9 115 57.5 
25-29.9 64 32.0 
≥ 30 19 9.5 
Total 200 100 
 
• 57.5% of the subjects had normal B.M.I.  
• 32% were overweight and 9.5% were obese. 
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BMI distribution in Nephropathy Group 
Table - 10 
BMI group (Kg/m2) No. of subject Percentage 
< 18.5 0 0% 
18.5-24.9 3 11.5% 
25-29.9 19 73.1% 
≥ 30 4 15.4% 
Total 26 100% 
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• Subjects having weight above the desired normal B.M.I. were 
88.5% in the Nephropathy group. Among them 73.1% and 15.4% 
were overweight and obese respectively. 
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26
Non nephropathy Nephropathy
Chart 5 
• 26 Patients were diagnosed to have Diabetic Nephropathy, 
24 of them had Microalbuminuria (Stage 3 Diabetic Nephropathy) 
and two of them had Macroalbuminuria (Stage 4 Diabetic 
Nephropathy). 
• Among the nephropathy group, 6 Patients had Diabetic 
Retinopathy. 
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• Among the study group of newly detected Diabetes Mellitus 46% of 
subjects had hypertriglyceridemia and subjects having raised LDL 
level and low HDL level were respectively 99% and 47% 
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Chart 8: Prevalence of Dyslipidemia
 
 43
Age and Diabetic Nephropathy 
Table - 11 
Nephropathy N Age Mean Std. 
Deviation 
Std. Error 
Mean 
 Yes 26 48.46 8.33 1.63 
 No 174 49.17 9.18 0.70 
   
P=0.710       Not significant 
 
BMI and Diabetic Nephropathy 
• Mean BMI among the non Nephropathy Group is 24.52. 
• Among the Nephropathy Group 26.79. 
Table. 12 
Nephropathy N BMI Mean Std. 
Deviation 
Std. Error 
Mean 
Yes 26 26.79 2.34 0.46 
No 174 24.52 3.58 0.27 
   
P=0.002        significant 
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Table - 13 
Nephropathy BMI 
group 
(Kg/m2) 
 
No Yes 
Total 
Count 2 0 2 
% Within Non Nephropathy & 
Nephropathy 
1.1% 0.0% 1.0% < 18.5 
% of Total 1.0% 0.0% 1.0% 
Count 112 3 115 
% Within Non Nephropathy & 
Nephropathy 
64.4% 11.5% 57.5% 18.5-
24.9 
% of Total 56.0% 1.5% 57.5% 
Count 45 19 64 
% Within Non Nephropathy & 
Nephropathy 
25.9% 73.1% 32.0% 25-
29.9 
% of Total 22.5% 9.5% 32.0% 
Count 15 4 19 
% Within Non Nephropathy & 
Nephropathy 
8.6% 15.4% 9.5% 30 & 
above 
% of Total 7.5% 2.0% 9.5% 
Count 174 26 200 
% Within Non Nephropathy & 
Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
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Serum creatinine and Diabetic Nephropathy 
Table - 14 
Nephropathy N Serum  
creatinine 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
Yes 26 0.82 0.11 0.02 
No 174 0.77 0.10 0.01 
P=0.019       Significant 
The mean Serum creatinine value in non-Nephropathy subjects is 
0.7 mg/dl and in Nephropathy group is 0.8 mg/ dl. 
Gender and Diabetic Nephropathy 
Table - 15 
Nephropathy Gender  
No Yes 
Total 
Count 68 2 70 
% Within Non Nephropathy & 
Nephropathy 
39.1% 7.7% 35.0% Male 
% of Total 34.0% 1.0% 35.0% 
Count 106 24 130 
% Within Non Nephropathy & 
Nephropathy 
60.9% 92.3% 65.0% Female 
% of Total 53.0% 12.0% 65.0% 
Count 175 26 200 
% Within Non Nephropathy & 
Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
χ2 = 9.796 
P = 0.002          Significant 
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Family History of Diabetes and Diabetic Nephropathy 
Table - 16 
Nephropathy FH/D  
No Yes 
Total 
Count 130 18 148 
% Within Non Nephropathy & 
Nephropathy 
74.7% 69.2% 74.0% No 
% of Total 65.0% 9.0% 74.0% 
Count 44 8 52 
% Within Non Nephropathy & 
Nephropathy 
25.3% 30.8% 26.0% Yes 
% of Total 22.0% 4.0% 26.0% 
Count 174 26 200 
% Within Non Nephropathy & 
Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
χ2 = 0.353 
P = 0.632              Not Significant 
 
• In total 26% of the Patients (52) were having family history of 
Diabetes. 
• Among the Nephropathy Patients 30.8% had family history of 
Diabetes mellitus. 
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Family History of Kidney diseases and Diabetic Nephropathy 
• Two of the Patients were having family history of Kidney diseases 
among the Nephropathy Group. 
• No such history was found in non-nephropathy group. 
Table - 17 
Nephropathy FH/KD  
No Yes 
Total 
Count 174 24 198 
% Within Non Nephropathy & 
Nephropathy 
100.0% 92.3% 99.0% 
No 
% of Total 87.0% 12.0% 99.0% 
Count 0 2 2 
% Within Non Nephropathy & 
Nephropathy 
0.0% 7.7% 1.0% 
Yes 
% of Total 0.0% 1.0% 1.0% 
Count 174 26 200 
% Within Non Nephropathy & 
Nephropathy 
100.0% 100.0% 100.0% 
Total 
% of Total 87.0% 13.0% 100.0% 
 
χ2 = 13.520 
P = 0.016               Significant 
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Smoking and Diabetic Nephropathy 
• Six subjects were found to be smokers in the subjects under the study 
and belonged to the non Nephropathy Group. 
Table - 18 
Nephropathy Smoking  
No Yes 
Total 
Count 168 26 194 
% Within Non Nephropathy 
& Nephropathy 
96.6% 100.0% 97.0% No 
% of Total 84.0% 13.0% 97.0% 
Count 6 0 6 
% Within Non Nephropathy 
& Nephropathy 
3.4% 0.0% 3.0% Yes 
% of Total 3.0% 0.0% 3.0% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
 
χ2 = 0.924 
 
P = 0.429          Not Significant 
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Dyslipidemia and Diabetic Nephropathy 
• TGL Group: 46% of the subjects had  Hypertriglyceremia   in the 
study group. It was 61.5% in the Nephropathy Subjects. 
• LDL Group: 99% of the subjects had LDL – Cholesterol                 
dyslipidemia in the study group.   It was 100% in the  Nephropathy 
subjects.        
• HDL Group: 47% of the subjects had HDL – Cholesterol               
dyslipidemia in the study group. It was 61.5% in the Nephropathy 
subjects. 
TGL Dyslipidemia 
Table - 19 
Nephropathy TGL 
Dyslipi-
demia 
 
No Yes 
Total 
Count 98 10 108 
% Within Non Nephropathy 
& Nephropathy 
56.3% 38.5% 54.0% No 
% of Total 49.0% 5.0% 54.0% 
Count 76 16 92 
% Within Non Nephropathy 
& Nephropathy 
43.7% 61.5% 46.0% Yes 
% of Total 38.0% 8.0% 46.0% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
 
χ2 = 2.905 
P = 0.096          Not Significant 
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LDL Dyslipidemia 
Table - 20 
 
Nephropathy LDL 
Dyslipi-
demia 
 
No Yes 
Total 
Count 2 0 2 
% Within Non Nephropathy 
& Nephropathy 
1.1% 0.0% 1.0% 
No 
% of Total 1.0% 0.0% 1.0% 
Count 172 26 198 
% Within Non Nephropathy 
& Nephropathy 
98.9% 100.0% 99.0% 
Yes 
% of Total 86.0% 13.0% 99.0% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% 
Total 
% of Total 87.0% 13.0% 100.0% 
 
χ2 = 0.302 
 
P = 1.000          Not Significant 
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HDL Dyslipidemia 
Table - 21 
 
Nephropathy HDL 
Dyslipi-
demia 
 
No Yes 
Total 
Count 96 10 106 
% Within Non Nephropathy 
& Nephropathy 
55.2% 38.5% 53.0% No 
% of Total 48.0% 5.0% 53.0% 
Count 78 16 94 
% Within Non Nephropathy 
& Nephropathy 
44.8% 61.5% 47.0% Yes 
% of Total 39.0% 8.0% 47.0% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
 
χ2 = 2.536 
 
P = 0.141          Not Significant 
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Hypertension and Diabetic Nephropathy  
• 11.5%  of the study subjects were found to be Hypertensive. 
• 34.6% of Nephropathy Patients were Hypertensive. 
Table - 22 
 
Nephropathy Hyper-
tension 
 
No Yes 
Total 
Count 160 17 177 
% Within Non Nephropathy 
& Nephropathy 
92.0% 65.4% 88.5% No 
% of Total 80.0% 8.5% 88.5% 
Count 14 9 23 
% Within Non Nephropathy 
& Nephropathy 
8.0% 34.6% 11.5% Yes 
% of Total 7.0% 4.5% 11.5% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
 
χ2 = 15.690 
 
P = 0.001         Significant 
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GFR  and Diabetic Nephropathy 
• 23%  of the subjects in the study group had Hyperfiltration.   
• One percent of Nephropathy group had Hyperfiltration.  
• Among the Nephropathy Patients 46.2% had a normal G.F.R.  The 
same percentage of the Nephropathy subjects had decreased G.F.R.  
Table - 23 
Nephropathy GFR 
Group 
(ml/min./ 
1.73m2) 
 
No Yes 
Total 
Count 0 12 12 
% Within Non Nephropathy 
& Nephropathy 
0.0% 46.2% 6.0% Low  
<90 
% of Total 0.0% 6.0% 6.0% 
Count 130 12 142 
% Within Non Nephropathy 
& Nephropathy 
74.7% 46.2% 71.0% Normal  
90-125 
% of Total 65.0% 6.0% 71.0% 
Count 44 2 46 
% Within Non Nephropathy 
& Nephropathy 
25.3% 7.7% 23.0% Hyper filteration 
>125 
% of Total 22.0% 1.0% 23.0% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
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Table - 24 
Nephropathy N GFR Mean Std. 
Deviation 
Std. Error 
Mean 
Yes 26 100.42 19.29 3.78 
No 174 117.47 17.31 1.31 
 
P=0.000 ( <0.001)       Significant 
Retinopathy and Diabetic Nephropathy 
• All the Six subjects found to have Retinopathy were under the 
Nephropathy group. 
Table - 25 
Nephropathy Retino- 
pathy 
 
No Yes 
Total 
Count 174 20 194 
% Within Non Nephropathy 
& Nephropathy 
100.0% 76.9% 97.0% No 
% of Total 87.0% 10.0% 97.0% 
Count 0 6 6 
% Within Non Nephropathy 
& Nephropathy 
0.0% 23.1% 3.0% Yes 
% of Total 0.0% 3.0% 3.0% 
Count 174 26 200 
% Within Non Nephropathy 
& Nephropathy 
100.0% 100.0% 100.0% Total 
% of Total 87.0% 13.0% 100.0% 
χ2 = 41.396 
P = 0.000 (<0.001)      Significant 
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BINARY LOGISTIC REGRESSION 
• Nephropathy has been taken as dependent variable. 
• The following variables are taken as models and Binary Logistic 
Regression model was applied to find out Correlation of the risk 
factors. 
1. Age Group 
2. Gender 
3. Family history of diabetes 
4. Family history of Kidney Diseases 
5. Smoking 
6. Body Mass Index 
7. Body Mass Index group 
8. Hypertension 
9. TGL Group 
10. LDL Group 
11. HDL Group 
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Table - 26 
Variables χ2 Significant 
Age 2.803 0.423 
31-40 (Years) 1.898 0.168 
41-50 (Years) 2.718 0.099 
51-60 (Years) 1.623 0.203 
Male gender 5.725 0.017 
Family H/o Diabetes Mellitus 0.978 0.323 
Family H/o kidney diseases 0.000 0.999 
Smoking 0.000 0.999 
BMI 12.923 0.005 
Normal  0.000 1.000 
Overweight 3.935 0.047 
Obese 1.229 0.268 
Hypertension 9.325 0.002 
TGL Group 0.090 0.764 
LDL Group 0.000 1.000 
HDL Group 0.016 0.898 
 
Binary regression model showed significant correlation between 
diabetic nephropathy and the following  risk factors : Male sex, body 
mass index esp. over weight and  hypertension.  
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DISCUSSION 
The prevalence of diabetic nephropathy in this study is compared 
with studies done in various races. A study, done in the Chennai urban 
region by Unnikrishnan et al. showed 23.9% prevalence of 
microalbuminuria and 2.2% of macroalbuminuria. In our study it is 12% 
of microalbuminuria and 1% of macroalbuminuria. The lesser prevalence 
may be because of uncontrolled hypertensive patients are excluded from 
our study, while in other studies they were included. And also in other 
studies highly sensitive methods like Immunoturbidometric assay were 
used for AER detection. In addition, the sample size is small in our study. 
Prevalence of macroalbuminuria is higher in the western population. 
Table - 27 
Study Place & Year 
Micro 
albuminuria 
(Stage 3 
nephropathy)
Macro 
albuminuria 
(Stage 4 
nephropathy) 
Nephropathy 
(Total) 
Unnikrishnan 
et al24 
Chennai, 
India,2004 
26.90% 2.20% 29.10% 
Wirta et al25 Finland, 1995 29.00% 4% 33.00% 
Collins et al 26 
Wetern samoa, 
1995 
22% 3.90% 25.90% 
This study 
KMCH, 
Chennai,2008 
12% 1% 13.00% 
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Correlation with various risk factors 
Micro albuminuria and macroalbuminuria are both considered 
together as diabetic nephropathy and its correlation with the study 
variables are analysed. It has been compared with available datas of 
Unnikrishnan et al.24, Chennai study (Chennai Urban Rural Epidemiology 
Study- CURES 45), and with studies done in western population like 
WIRTA et al.25, Finland 1995; COLLINS et al26; Western Samoa, 1995 & 
UKPDS Studies3. 
Correlation Between AGE and Diabetic Nephropathy 
  Mean age in this study group is comparable with CURES study. 
Table - 28 
Study Mean Age 
This study 49 ± 9 
Unnikrishnan et al 51 ± 11 
 
In this study no correlation between Age and Diabetic Nephropathy 
was found. This is in contrast to the observation noted in Unnikrishnan et 
al study where as the age advances the risk of Diabetic nephropathy had 
increased. 
 59
Table - 29 
 AGE MEAN  
Study 
Non 
Nephropathy 
(Yrs) 
Nephropathy 
(Yrs) P value 
Unnikrishnan et al 50 ± 11 
52 ± 11*/  
57 ± 9** 
< 0.0001 
This study 49 ±  9 48 ± 8 0.710 
* Microalbuminuria 
** Macroalbuminuria 
No significant difference is seen between the Age of the Diabetic 
patient and development of Diabetic Nephropathy. 
Correlation Between Gender and Diabetic Nephropathy 
In this study it was found that there is a significant correlation 
noted in between Gender and Diabetic Nephropathy. Binary regression 
model showed that significant correlation exists between male sex and 
Diabetic Nephropathy (P = 0.017). 
In contrast, Unnikrishnan et al study showed no correlation 
between Gender and Diabetic Nephropathy. Various western studies had 
shown that  male patients had increased risk of development of diabetic 
nephropathy4. 
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Correlation Between Family History of Diabetes and Diabetic 
Nephropathy 
In this study there is no significant correlation between Family 
History of Diabetes and  development of Diabetic Nephropathy.  
Table - 30 
Family History of Diabetes 
Non Nephropathy Nephropathy P value 
44 8 0.632 
 
Correlation Between Family History of Kidney Diseases and Diabetic 
Nephropathy 
There is a significant correlation between Family History of 
Kidney Diseases and  development of Diabetic Nephropathy.  
Table - 31 
 
Family History of Kidney Diseases 
Non Nephropathy Nephropathy P value 
0 2 0.016 
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Correlation Between Smoking and Diabetic Nephropathy 
In this study there is no significant correlation between Smoking 
and  development of Diabetic Nephropathy.  
Table - 32 
Smoking 
Non Nephropathy Nephropathy P value 
6 0 1.000 
 
In contrast in Unnikrishnan et al study there was a significant 
correlation was found. The small size of the study population and with 
less number of patients had the history of smoking are the major 
limitations  in our study. 
Correlation Between BMI and Diabetic Nephropathy 
Patients having over weight showed significant development of 
Diabetic nephropathy. 
Table - 33 
BMI Mean 
Non Nephropathy Nephropathy P value 
24.51+ 3 26.78+ 2 0.002 
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Correlation Between Hypertension and Diabetic Nephropathy 
There is a highly significant correlation exist between 
Hypertension and Diabatic Nephropathy in this study and also in 
Unnikrishnan et al study. 
Table - 34 
Hypertension 
Study 
Non 
Nephropathy Nephropathy P value 
Unnikrishnan et al 40.80% 59.70% <0.001 
This study 14(8%) 9(34.6%) 0.001 
 
In our study hypertensive subjects having optimum controlled 
Blood pressure are only included .So the bias of Albuminuria caused by 
hypertension itself is avoided in this study. Even then also the 
hypertensive patients had increased risk of nephropathy due to 
hypertensive vascular pathology caused by previously uncontrolled or 
delayed detection of Hypertension as well as type 2 diabetes. So this 
study signifies that screening and early detection of hypertensive subjects 
and also the effective control of systemic pressure in spite of diabetic 
status (including Latent Diabetes) is  must. 
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Correlation Between Dyslipidemia and Diabetic Nephropathy 
Table - 35 
TGL Dyslipidemia 
Non Nephropathy Nephropathy P value 
76 16 0.096 
 
Table - 36 
LDL Dyslipidemia 
Non Nephropathy Nephropathy P value 
172 26 1.000 
 
Table - 37 
HDL Dyslipidemia 
Non Nephropathy Nephropathy P value 
78 16 0.141 
 
The subjects presented with Nephropathy had TGL, LDL & HDL 
Dyslipidemia with the prevalence of 61.5%, 100% and 61.5% 
respectively. 
The prevalence in total subjects ( Newly detected Diabetes 
Melitus) is 46%, 99% & 47%  respectively. 
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This shows high prevalence of hypertryglyceridemia, high LDL 
cholestrol levels and low HDL cholesterol levels in Type II diabetes 
mellitus as well as in Diabetic nephropathy subgroup. 
There is no statistical significance has been seen in this study 
between Dyslipidemia  and  diabetic nephropathy. 
Various other studies had shown significant relation between 
dyslipidemia and nephropathy. This may be because of the small size of 
our study population and also the high prevalence of the Dyslipidemia 
among the all newly detected Diabetes mellitus patients in our study. 
Correlation Between GFR and Diabetic Nephropathy 
GFR has significant correlation with Diabetic Nephropathy in this 
study. 
Table - 38 
GFR Mean GFR Mean 
Non Nephropathy Nephropathy 
P value 
117( + 17) 100 ( +19) 0.000  (<0.001) 
 
50 percent of the Nephropathy subjects had lower GFR depending 
on the severity of the disease. 
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Among non –nephropathic subjects one fourth had Hyperfiltration 
suggestive of stage I Diabetic Nephropathy. 
The mean GFR in total subjects (Newly detected type 2 Diabetes 
mellitus) is 115 + 18 ml/min/ 1.73 sq.m. 
Correlation Between Retinopathy and Diabetic Nephropathy 
Retinopathy was found to have highly significant correlation 
between Nephropathy. Retinopathy patients had increased risk of 
developing Nephropathy. 
About one fourth of the Nephropathy subjects in this study had 
presented with Diabetic Retinopathy. 
The prevalence of retinopathy in this study is lesser and it may be 
because of using direct opthalmoscope for the fundus examination 
whereas fundul photography was used in  other studies. 
Table - 39 
STUDY Prevalence of retinopathy 
Mohan Rema et al 5.10% 
This Study 3% 
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CONCLUSION 
1. In this study the prevalence of Diabetic Nephropathy in newly 
deducted type 2 diabetes mellitus is found to be significant. The 
study signifies the early screening of all Newly diagnosed type 2  
Diabetic patients for Diabetic Nephropathy. 
2. This study has shown significant association between the 
development of Nephropathy and risk factors like Family history of 
kidney diseases, Body Mass Index esp. with overweight, gender, 
systemic Hypertension, Serum creatinine, Glomerular filtration rate 
and Retinopathy. Binary regression model analysis showed 
significant association with male sex, over weight and  
hypertension. 
3. This study has not shown significant association of smoking and 
dyslipidemia with the development of Diabetic Nephropathy.  
4. Albumin Excretion Rate is the gold standard screening as well as 
diagnostic tool for the early diagnosis of Diabetic Nephropathy. 
Micral dip stick test method and the cost effective protein 
creatinine Ratio can be used as the valuable screening test in 
setting like our country where most of the population are in the low 
socio economic status. 
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5. Effective measures to control the risk factors and early detection of 
diabetic nephropathy to prevent it from progressing towards End 
Stage Renal disease is the key in maintaining the quality of life in 
Diabetic population. This not only decreases the morbidity and 
mortality among the Diabetic patients but also lessen the Financial 
burden faced on treating  such complications enormously, in the 
developing countries like India. 
6. The presence of complications at the time of diagnosis of type 2 
diabetes itself shows that intensive screening for early detection of 
diabetes mellitus and tight glycaemic control as well as Blood 
pressure control will prevent the development of microvascular 
complications. 
 68
SUMMARY 
 
This study was aimed to find out the prevalence of Diabetic 
Nephropathy in newly detected type 2 Diabetic patients and also the risk 
factors associated with the development of the Diabetic nephropathy. 
The prevalence found in this study was 13 percent. Among these 
patients 12 percent had microalbuminuria and one percent had 
macroalbuminuria. 
The risk factors found to be having significant association are 
family history of kidney diseases, overweight, male gender, systemic 
hypertention, serum creatinine, glomerular filtration rate and retinopathy. 
The active screening and early detection of type 2 diabetes is 
necessary. Hence the measures to create awareness among the people and 
educate them for a healthy life style are to be taken.  
The effective control of the risk factors in type 2 diabetic patients 
will prevent the development of nephropathy and also retards it’s 
progression. 
ABBREVIATION 
ACE Inhibition - Angiotensin converting enzyme inhibitor 
AER   - Albumin Excretion Rate 
BMI   - Body mass Index 
CCBs   - Calcium channel blockers 
CVD   - Cardiovascular disease 
DM   - Diabetes mellitus 
DNA   - Deoxyribonucleic acid 
ESRD  - End Stage Renal Disease 
GBM   - Glomerular Basement Membrane 
GFR   - Glomerular Filtration Rate 
HDL   - High Density Lipoprotein 
IDDM  - Insulin Dependent diabetes mellitus 
LDL   - Low Density Lipoprotein 
MDRD  - Modification of diet in renal disease 
MPGN  - Membrano Proliferative Glomerular Nephritis 
NIDDM  - Non insulin dependent diabetes mellitus 
OGTT  - Oral Glucose Tolerance Test 
PCR   - Protein creatinine ratio 
TGL   - Triglyceride 
UAER  - Urinary Albumin Excretion Rate 
UKPDS  - United Kingdom Prospective Diabetes Study 
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P 
 
PROFORMA 
 
Name of the patient  : 
IP/OP No    : 
Age     : 
Sex     : 
Address    : 
 
 
H/O smoking   : 
H/O hypertension   : 
Family H/O diabetes  : 
Family H/O kidney disease : 
Height    : 
Weight    : 
BMI     : 
 
Blood pressure   : 
Lipid profile   : 
 TGL    : 
 LDL    : 
 HDL    : 
 
 
RFT     
 Blood urea   : 
 Serum creatinine  : 
GFR     : 
Urine routine   : 
 Sample 1 
 Sample 2 
 Sample 3 
Urine culture   : 
Urine PCR    : 
 Sample 1 
 Sample 2 
 Sample 3 
Dipstick(MICRAL)test  : 
 Sample 1 
 Sample 2 
 Sample 3 
USG KUB    : 
 
 
Fundus examination  : 
 
 
 
 
